ANX 007
Alternative Names: Anti-C1q therapy - Annexon; ANX-007Latest Information Update: 22 May 2025
At a glance
- Originator Annexon
- Class Antiglaucomas; Eye disorder therapies; Fab fragments; Monoclonal antibodies
- Mechanism of Action Complement C1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry macular degeneration
- No development reported Open-angle glaucoma
Most Recent Events
- 12 May 2025 Annexon announces intention to submit regulatory application for Geographic atrophy secondary to age related macular degeneration in USA and Europe
- 14 Nov 2024 Efficacy data from the phase II ARCHER trial in Dry macular degeneration released by Annexon Biosciences
- 21 Oct 2024 Efficacy data from a phase II ARCHER trial in Dry macular degeneration released by Annexon Biosciences